A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects
A Double-Blind, Placebo-Controlled, Randomised, Dose-Escalation Phase I Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a phase I study in healthy women aged 18 to 50 years, which involves vaginal application of study drug P2G12 or placebo.
P2G12 is a monoclonal antibody (MAb) (a kind of protein), and belongs to a group of MAbs that can help to prevent and protect from HIV infection. Most of these MAbs have been produced using a system called Chinese Hamster Ovary cell (CHO-Cell) fermentation, e.g. C2G12. This method of production is very expensive and cannot produce enough MAbs on a scale required for the global market.
Unlike C2G12, P2G12 is manufactured from plants. It is hoped that plant manufacture of such MAbs may offer some solutions to the high cost and low output of CHO-cell fermentation.
This study is designed to confirm the safety of a vaginally delivered MAb (P2G12) derived from plants and manufactured to Good Manufacturing Practice (a quality standard used for the manufacture of medicinal products).
11 subjects will be enrolled consecutively in cohorts (groups); in each successive cohort a higher dose of study drug will be administered, as well as placebo. The dose range is from up to 7 to up to 28mg of P2G12 in saline.
Subjects attend 7 visits over 13 weeks. At visit 3 subjects receive a single administration of study drug/placebo. Study visits include the following procedures: physical exam, vital signs, blood and urine samples, cervical smear test and colposcopy (medical examination of the cervix).
The relationship of adverse events (AEs) and serious adverse events (SAEs) to P2G12 administration, and abnormal laboratory test results as compared to baseline (pre-dose) values, will determine the safety of P2G12 in the study.
Levels of P2G12 in vaginal and serum samples will be measured at particular time-points in order to understand how quickly P2G12 is broken down by the body (pharmacokinetics) and whether any P2G12 is absorbed into the systemic circulation.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Surrey
-
Guildford, Surrey, Reino Unido, GU2 7XP
- Surrey Clinical Research Centre
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- A female adult subject aged between 18 and 50 years old.
- They are in good health as determined by medical history, physical examination and clinical judgement before entering into the study.
- Subjects must agree to abstain from vaginal sexual intercourse for 72 hours before and after dosing.
- Subject must agree not to undertake any vaginal practices during study participation other than receptive intercourse with a male, or use of sanitary tampons during menses. Use of condoms without spermicidal agents is encouraged.
- Confirmation from the subject's GP that there is nothing in the subject's medical history that would prevent the subject from participating in the study.
Exclusion Criteria:
- They have a known or suspected ongoing vaginal disease, malignancy or abnormality (including non-menstrual vaginal discharge) discovered at time of screening.
- They have an abnormality, or non-menstrual discharge noted at screening colposcopy.
They present in the samples obtained at the screening visit:
- positive results for HIV 1 or 2 antibody.
- positive results for Hepatitis B sAg, anti-Hepatitis C antibody
- positive syphilis serology
- positive test for Neisseria gonorrhoea or Chlamydia trachomatis on urine or urethral swab sample
- abnormal cervical smear cytology
- A clinically significant amount of protein or haemoglobin in the urine sample, determined by urine dipstick.
- They have received any form of immunosuppressive or immunomodulatory (e.g. vaccines) therapy in the past 6 months.
- They are receiving any medications via vaginal route.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Up to 7mg P2G12
|
A single intravaginal administration of 1ml P2G12/placebo.
|
|
Experimental: Up to 14mg P2G12
|
A single intravaginal administration of 1ml P2G12/placebo.
|
|
Experimental: Up to 28mg P2G12
|
A single intravaginal administration of 1ml P2G12/placebo.
|
|
Comparador de Placebo: Placebo (saline solution)
|
A single intravaginal administration of 1ml P2G12/placebo.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Occurrence, intensity and relationship to P2G12 administration of local and general adverse events (AEs) throughout the study period after drug administration.
Prazo: 35 days.
|
35 days.
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Changes in levels of P2G12 in blood and vaginal secretions as compared to baseline.
Prazo: 35 days
|
35 days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Hubert A Bland, MBChB, University of Surrey
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por Lentivírus
- Infecções por Retroviridae
- Doenças do sistema imunológico
- Doenças de Vírus Lento
- Infecções por HIV
- Síndrome da Imunodeficiência Adquirida
- Síndromes de Deficiência Imunológica
Outros números de identificação do estudo
- CRC282
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .